^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zilovertamab vedotin (MK-2140)

    i
    Company:
    Merck (MSD)
    Drug class:
    Microtubule inhibitor, ROR1-targeted antibody-drug conjugate
    Related drugs:
    Apply
    A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002) (NCT04504916)
    Phase 2
    VelosBio Inc.
    Completed
    Last update posted :
    06/29/2023
    Initiation :
    10/07/2020
    Primary completion :
    06/12/2023
    Completion :
    06/12/2023
    HER-2
    |
    HER-2 negative
    |
    zilovertamab vedotin (MK-2140)